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Abstract.  Recent results showing that a  single 
fibronectin gene can give rise to several different 
mRNAs by alternative splicing have offered an expla- 
nation for fibronectin polymorphism. Here we report 
on monoclonal antibodies that show specificity for a 
fibronectin segment (ED) that can be included or 
omitted from the molecule depending on the pattern of 
splicing of the mRNA precursors.  Using these 
monoclonals,  we have quantitatively analyzed the ex- 
pression of the ED sequence in human fibronectin 
from different sources.  The results demonstrated that, 
at the protein level, the ED segment is not expressed 
in plasma fibronectin and that,  in fibronectin from the 
tissue culture medium of tumor-derived or simian 
virus-40-transformed human cells,  the percentage of 
fibronectin molecules containing the ED segment is 
about  10 times higher than in fibronectin from normal 
human fibroblasts.  These results suggest that in malig- 
nant cells the mechanisms that regulate the  splicing of 
mRNA precursors are altered. 
F  IBRONECT1NS (FNs) ~  are high-molecular-mass, adhe- 
sive  glycoproteins present  in  the  soluble  form  in 
plasma and other body fluids and in insoluble form 
in the extracellular matrices and basement membranes. FN 
molecules act as bridges between the cell surface and ex- 
tracellular material. In fact, the FN molecules contain a cell- 
binding site and binding sites for collagen, heparin, ganglio- 
sides, and fibrin. Because of their multiple interactions, FNs 
play an important role in diverse biological phenomena, in- 
cluding cell adhesion, cell migration, hemostasis and throm- 
bosis, wound healing and the ability to induce a more normal 
phenotype in transformed cells (for reviews on distribution, 
structure,  and biological functions,  see references 1,  7,  8, 
18, 24). 
It has been demonstrated that FN polymorphism may be 
at least partially due to alternative splicing schemes in two 
regions  (ED  and  IIICS)  because as  many as  10  different 
mRNAs may originate from the primary transcript of  a single 
gene (9,  12-15, 25, 26, 29) localized on chromosome 2 (11, 
34). In fact, Schwarzbauer et al. (25) have shown that an an- 
tiserum specific for the rat fibronectin IIICS sequence recog- 
nizes the larger subunit of rat plasma FN (plFN), but not the 
smaller one. 
Here we report the characterization of mAbs for the ED 
1. Abbreviations  used in this paper:  cFN and plFN, fibronectin from cul- 
tured cell media and plasma, respectively. 
fragment of fibronectin. Using these mAbs in a quantitative 
assay, we have demonstrated that this sequence is not present 
in plFN and that tumor-derived and SV-40-transformed hu- 
man cells release a population of FN molecules in which the 
percentage of subunits containing the ED sequence is about 
10 times higher than in the FN released by normal human 
fibroblasts. 
Materials and Methods 
Materials 
Eagle's  minimum  essential  medium  (MEM)  was  obtained  from  Flow 
Laboratories Inc. (Irvine, Scotland). FCS was obtained from Sera-Lab (Sus- 
sex, England). Thermolysin (protease type X),  cathepsin D,  pemxidase, 
concanavalin A,  pepstatin A,  BSA,  phenylmethylsulfonyl fluoride,  and 
3-(cyclohexylamino) propane sulfonic acid were purchased from Sigma 
Chemical Co. (St. Louis, MO).  Protein A-Sepharose, cyanogen bromide- 
activated-Sepharose 4B, and heparin-Sepharose CL-6B were obtained from 
Pharmacia  Fine  Chemicals  (Uppsala,  Sweden).  Hydroxyapatite (DNA- 
grade),  acrylamide, bisacrylamide, SDS,  and  low- and high-molecular- 
mass calibration kits were obtained from Bio-Rad Laboratories (Richmond, 
CA). Nitrocellulose was from Schleicher & Sch/ill (Kassel, Federal Repub- 
lic of Germany).  Polyvinyl microwell plates were obtained from Cooke 
Labs  (Alexandria,  VA).  Peroxidase-conjugated wheat  germ  agglutinin, 
peanut agglutinin, and Ricinus communis  agglutinin were from Miles-Yeda 
(Rehovot,  Israel).  Peroxidase-conjugated  antibodies  were  from  Dako 
(Copenhagen, Denmark).  Aprotinin was  obtained  from  Lepetit (Milan, 
Italy).  Other chemicals were reagent-grade reagents from Merck (Darm- 
stadt, Federal Republic of Germany). 
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Cultured normal human fibroblast lines (LZ and GM-3651-1C from adult 
human skin, GM-5386 from embryonic human skin, and WI-38 from em- 
bryonic human lung) and transformed cell lines (HT-1080 from a human 
fibrosarcoma, RD from an embryonic human rhabdomyosarcoma, IgR3 
from a human melanoma, WI-38VA13, and SV-40-transformed WI-38 cells) 
were  grown  in  MEM  supplemented with  10%  FCS,  which had  been 
depleted  of  bovine  FN  by  passage  through  a  large-capacity  gelatin- 
Sepharose column. The fR5 is an SV-40-transformed human mammary epi- 
thelial cell line (4). 
Monoclonal Antibodies 
Six mAbs to different human FN epitopes were used. The mAb 3E3 (23), 
directed to the cell-binding region of FN,  was a  gift from Drs.  M.  D. 
Pierschbacher and E. Ruoslahti (La Jolla Cancer Research Foundation, La 
Jolla, CA). The characterization of the mAbs IST-2,  IST-7, and IST-4 has 
been previously reported (3, 28, 33). They are specific both for plFN and 
cell media-cultured FN (cFN). In particular, the epitope recognized by IST- 
2 is localized within the first three type III homology repeats of the heparin- 
binding domain (see Fig. 3) (3, 28); the epitope recognized by IST-7 within 
the last type III homology repeat of the FN molecule (3) (see Fig. 3), and 
the epitope of IST-4 within the first four type III homology repeats of the 
FN molecule (28). All three of these mAbs were elicited using plFN as an- 
tigen. 
The mAbs FN-3 (10) and IST-9, both specific for cFN only, were obtained 
using as antigens the SV-40-transformed human mammary epithelial fR5 
cell line (4), and cFN from WI-38VA13 cells, respectively. 
Purification of  Antibodies and Preparation 
of lmmunoadsorbents 
Unique  monoclonal  hybridomas  were  expanded  as  ascites  tumors  in 
syngenic mice. Antibodies were purified from these ascites with protein 
A-Sepharose equilibrated with borate-buffered saline at pH 8.3. These anti- 
bodies were then coupled to cyanogen bromide-activated Sepharose 4B ac- 
cording to the manufacturer's instructions. This resulted in a coupling of an 
average of 2 mg IgG/ml of gel. 
Purification and Proteolytic  Digestion of  FN 
FNs were purified from human plasma and from the conditioned media of 
the various cell lines as previously reported (35). Thermolysin digestion of 
FN was performed as described by Sekiguchi and Hakomori (27). Cathepsin 
D digestion of FN was performed according to Balian et al. (2).  SDS PAGE 
and immunoblotting were carded out as described (16, 31). 
Purification and Thermolysin Digestion of FN 
Fragments Containing the Immunological Determinant 
Recognized by the mAb 1ST-9 
About 200 nag of cFN from WI-38VAI3 cells in 250 mi of 50 mM sodium 
acetate buffer, pH 3.5,  1.8 mM 3-(cyclohexylamino) propane sulfonic acid, 
0.5  mM  EDTA,  0.2  mM  phenylmethylsulfonyl fluoride,  and  10  kal- 
lidinogenase inhibitor units/ml of aprotinin was digested with 2.5 gg/mi of 
cathepsin D for 4 h at 30°C. Cathepsin D was chosen because preliminary 
experiments indicated that the immunological determinant recognized by 
IST-9 was quite resistant to this enzyme. This first step was required to avoid 
FN precipitation (owing to the low solubility of intact cFN) during the sec- 
ond step, adsorption of FN on IST-9-Sepharose. Cathepsin D digestion was 
stopped by the addition of a  10-fold molar excess of pepstatin A, and the 
sample was neutralized with 2.5 M Tris, pH 8.8. After dialysis against PBS 
containing 0.1% NaN3 and 20 kallidinogenase inhibitor units/ml of aproti- 
nin, the FN  digest was added to 20  ml  of IST-9-Sepharose previously 
equilibrated in the same buffer. After slow rotation in an end-over mixer for 
4 h at room temperature, the IST-9-Sepharose was transferred to a chroma- 
tography column and washed with PBS. When all the unbound polypeptides 
were washed out, the immunoadsorbent was washed with 25 mM Tris-HCl 
buffer, pH 7.6, 0.5 mM EDTA, 50 mM NaCI, and 2.5 mM CaCI2. The 20 
ml of immunoadsorbent were then resuspended in 20 mi of the same buffer, 
and thermolysin digestion was carried out directly in the chromatography 
column, adding 100 I.tg of thermolysin (final concentration 2.5 gg/mi). Af- 
ter slow rotation of the chromatography column in an end-over mixer for 
3 h at room temperature, the reaction was stopped by adding EDTA (5 mM 
final concentration) and the released polypeptides were washed out by PBS. 
The bound polypeptides were then eluted by 0.2 M glycine buffer, pH 2.7. 
The eluting fractions were immediately neutralized by 2.5 M Tris, pH 8.8. 
Analysis in SDS PAGE of the eluting material showed two polypeptides of 
44 and 47 kD plus a small amount of a 52-kD fragment. Purification of each 
of these fragments was obtained by fractionation on a hydroxyapatite chro- 
matography column (the detailed procedure will be described elsewhere, 
Borsi, L., and L. Zardi, manuscript in preparation). These purified frag- 
ments were then redigested by thermolysin (0.5 ~tg/ml) for 1 h, and the poly- 
peptides obtained were purified on a hydroxyapatite chromatography col- 
umn (32). 
Microsequence Analysis 
FN fragments were desalted on a Vydac C4 column (4.5  ×  250 mm; The 
Separations Group, Hesperia, CA) using a linear gradient from solvent A 
(0.1% aqueous trifluoroacetic acid) to 70 % solvent B (0.1:9.9, trifluoroacetic 
acid/H20/CH3CN) over a 70-rain period at a flow rate of 44 ml/h. Detec- 
tion was performed at 214 nm using equipment previously described (19)• 
Samples (70 pmol) were subjected to automated Edman degradation on a 
gas-phase instrument built at the City of Hope (5). Amino acid phenylthio- 
hydantoin derivatives were analyzed by reverse-phase HPLC as previously 
described (6)• 
Interaction of  Fibronectin Fragments with mAbs, 
Lectins, and Heparin 
The reaction of fibronectin proteolytic fragments with mAbs, concanavalin 
A, wheat germ agglutinin, Ricinus communis agglutinin, and peanut agglu- 
tinin was determined, after transfer of polypeptides from SDS PAGE to 
nitrocellulose sheets, as previously described (32). Interaction of the differ- 
ent FN fragments with heparin was studied as reported (32). 
Radioimmunoassay 
Hybrids were screened for secretion  of  anti-FN antibodies by the previously 
described (33) solid-phase double-antibody radioimmunoassay procedure 
using both purified plFN and cFN as antigens. Only clones showing a nega- 
tive reaction for plFN and a positive reaction for cFN were selected for fur- 
ther characterization. The solid-phase double-antibody radioimmunoassay 
method was also used for the quantitative competition binding assay (3, 36). 
It was carried out using the mAbs IST-9 and FN-3 (both specific for the ED 
sequence), and IST-4 (specific for a sequence common to all FN variants). 
Various dilutions of different FNs in PBS, containing 3 % BSA and 10 kal- 
lidinogenase inhibitor units/mi of aprotinin, were incubated with the mAbs 
(at a dilution that had given 50% of maximum binding in titration experi- 
ments) for 2 h at 370C. The mixtures were then transferred into the wells 
of polyvinyl plates previously coated with purified cFN and incubated for 
2 h. The mixture was then removed and the wells were washed with PBS. 
The  amount  of antibody bound was  measured  by  adding  specific  ~25I- 
labeled rabbit anti-mouse Ig and incubating for 2 h. The entire procedure 
was carried out at room temperature. 
Protein Determination 
Protein concentrations of fibronectin and its fragments were estimated spec- 
•  1%  trophotometrically at 280 nm using an absorption coefficient of E~m =  12.8 
(17). 
Results 
The mAb IST-9 Is Specific  for the ED Sequence 
The capacity of the mAb FN-3 to distinguish between human 
cellular and plasma FN has been previously reported (10). 
A similar capacity was also established for the mAb IST-9 
using both the radioimmunoassay and immunoblotting pro- 
cedures described in Materials and Methods. 
Preliminary attempts to purify a proteolytic fragment con- 
taining the immunological determinant recognized by the 
mAb IST-9 were frustrating because of the high sensitivity 
of this determinant to proteolytic enzymes. Thus, we have 
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fragments obtained from IST- 
9-Sepharose affinity chroma- 
tography column.  (A) 4-18 % 
SDS PAGE: lanes I and 2, 10 
and 2 ~tg, respectively, of FN 
fragments  eluted  by  glycine 
buffer, pH 2.7, from the IST- 
9-Sepharose  immunoadsor- 
bent after thermolysin diges- 
tion; lanes 3, 4, and 5, purified 
44-, 47-, and 52-kD fragments. 
S, molecular mass standards. 
(B) Immunoblot of a  4-18% 
SDS  PAGE probed  with  the 
mAb IST-9. Lanes 2, 3, 4, and 
5 as in A. The values on the 
right are molecular mass. 
elaborated the purification protocol described in Materials 
and Methods. 
After incubation of the cFN-cathepsin D digest with IST- 
9-Sepharose, the bound polypeptides were digested directly 
on the IST-9-Sepharose immunoadsorbent by thermolysin. 
In  this  way  we protected the  immunological  determinant 
from the proteolytic enzyme. After washing out the released 
material with PBS, the bound polypeptides were eluted by 
glycine buffer, pH  2.7.  Analysis  on a  4-18 %  SDS  PAGE 
of these polypeptides showed two main  fragments having 
Table I. NH2-terminal Sequence Analysis of FN Fragments 
Eluted from IST-9-Sepharose  (52, 47, and 44 kD) 
and of Those Obtained by Their Subsequent Thermolysin 
Digestion (38, 33, and 30 kD) 
Mr of the fragments 
Cycle 52  47  44  38  33  30 
1  Ile (20)  Ile (30)  Ile (23)  Ile (28)  Leu (41)  Leu (40) 
2  Asp (26)  Asp (37)  Asp (29)  Gly (16)  lie (45)  lie (25) 
3  Arg (12)  Arg (21)  Arg (14)  Thr (10)  Gly (56)  Gly (14) 
4  Pro (45)  Pro (53)  Pro (51)  Gin (26)  Thr (41)  Thr (14) 
5  Lys (44)  Lys (86)  Lys (49)  Ser (4)  Gin (35)  Gin (33) 
6  Gly (20)  Gly (32)  Gly (25)  Ser (13)  Ser (4) 
7  Leu (26)  Leu (48)  Leu (31)  Thr (25)  Thr (12) 
8  Ala (40)  Ala (37)  Aia (44)  Ala (11)  Ala (25) 
9  Phe (27)  Phe (13)  Ile (13) 
10  Thr (NQ)  Thr (NQ)  Pro (14) 
11  Asp (32)  Asp (35)  Ala (21) 
12  Val (51)  Val (22)  Pro (16) 
13  Asp (19)  Asp (32)  Thr (NQ) 
14  Val (27)  Val (21)  Asp (NQ) 
15  Asp (13)  Asp (15)  Leu (13) 
16  Ser (NQ)  Ser (10) 
17  Ile (21) 
Values in parentheses are in picomoles. NQ, residue detected but not quan- 
titated. 
molecular masses of  47 and 44 kD, respectively, plus a minor 
one of 52 kD (Fig.  1 A). All three fragments showed a posi- 
tive reaction with the mAbs IST-9 and IST-2 in immunoblot 
analysis (Fig.  1 B), whereas only the 52-kD fragment re- 
acted with IST-7 (see Fig.  3).  Each of the three fragments 
was  purified on a  hydroxyapatite chromatography column 
(Fig.  1). All three showed a high affinity for heparin, only 
the 47-kD fragment reacted with wheat germ agglutinin and 
Ricinus  communis  agglutinin.  Comparison  of  the  NHz- 
amino acid sequences of these three polypeptides with the 
FN  sequence  (12) demonstrated  that  all three contain the 
complete ED sequence at their NH2-terminal (Table I). In 
the 44- and 47-kD fragments, the last type III homology re- 
peat is lacking (negative reaction with IST-7) because of the 
presence of the IIICS sequence, which introduces into the 
FN molecule, a site extremely sensitive to the proteolytic en- 
zyme thermolysin (3).  The difference in mass between the 
44- and 47-kD fragments is due to differences in carbohy- 
drate content as indicated by the different reactivity with lec- 
tins. In fact, we have previously demonstrated that some FN 
molecules are sialylated in this region (3). The 52-kD frag- 
ment also contains the last type III homology repeat (positive 
reaction with IST-7); this is due to the fact that this fragment 
originates from FN subunits in which the IIICS sequence is 
completely deleted, conferring to this polypeptide resistance 
to thermolysin (3). 
Because the determinant recognized by IST-9 is very sensi- 
tive to thermolysin while on the contrary, the heparin-bind- 
ing domain is extremely resistant (3), we mildly digested the 
three purified fragments with thermolysin.  We obtained a 
38-kD fragment from the 52-kD, a 33-kD fragment from the 
47-kD, and a 30-kD fragment from the 44-kD (Figs. 2 and 
3). All fragments (30, 33, and 38 kD) lost their ability to in- 
teract with IST-9, but not with IST-2. The 38-kD fragment 
was still able to react with the mAb IST-7 and the 33-kD with 
wheat germ  agglutinin  and Ricinus  communis  agglutinin. 
The  amino  acid  sequence  of the  NH2-terminal  of these 
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purified FN fragments containing the ED sequence. Lane I:  4- 
18 % SDS PAGE  of  a thermolysin digest of  polypeptides eluted from 
the IST-9-Sepharose (shown in Fig. 1 A, lane 1). Lanes 2 and 3: 
the two purified main fragments obtained by thermolysin digestion 
of the 47- (lane 2) and 44- (lane 3) kD fragments, respectively. S, 
molecular mass standards. 
three polypeptides showed that the ED sequence was cleaved 
(Table I). These three fragments have characteristics identi- 
cal  to  the  heparin-binding  fragments usually  obtained by 
thermolysin digestion of cFN (3). Identical results were ob- 
tained using the mAb FN-3. 
Quantitative Determination of the ED Sequence 
in FN  from Different Sources 
To estimate the presence of the ED sequence in FN from 
different sources, we used the mAbs IST-9 (which recognizes 
the ED sequence) and IST-4 (which recognizes a determinant 
common to all FN types) in a competition radioimmunoas- 
say system (for procedure see Materials and Methods). 
The results, summarized in Table II, demonstrated that the 
ED  sequence is  undetectable in plasma  FN,  and that the 
amount of FN  molecules containing the  ED  sequence is 
about 10 times higher in FN from SV-40-transformed or tu- 
mor-derived human cells than from normal cells. 
Discussion 
Here we report on mAbs (IST-9 and FN-3) specific for the 
ED sequence of human FN. The localization within the ED 
sequence of the epitopes recognized by these mAbs is based 
on the following observations:  (a) these mAbs react only 
with cFN and not with plFN. This result is consistent with 
experiments showing that the ED segment is absent in hepa- 
tocyte mRNAs that are the source of plFN (14, 30). (b) The 
ED sequence is easily destroyed by very mild thermolysin 
digestion. However, this sequence becomes very resistant to 
thermolysin when FN is bound to the mAbs IST-9 or FN-3. 
(c)  All  of the thermolysin fragments that bind  to an  im- 
munoadsorbent prepared with the mAbs IST-9 or FN-3 con- 
tain the complete ED sequence at the NH2-terminal (see Ta- 
ble I).  The fact that the 44- and 47-kD FN fragments are 
positive for IST-9 and FN-3 even though they lack the last 
type  III  homology  repeat  (negative  reaction  with  IST-7) 
demonstrates that the epitope recognized by IST-9 and FN-3 
is localized in an NH2-terminal position with respect to the 
last type III homology repeat (see Fig.  3).  Furthermore, 
when the ED sequence is removed from these three polypep- 
tides (44, 47, and 52 kD) by subsequent thermolysin diges- 
tion (Table I, Fig. 3), all of them lose the ability to react with 
the mAbs IST-9 and FN-3.  However, the 38-kD fragment 
(originating from the 52-kD fragment) still includes the last 
type III homology repeat. Thus, the epitopes recognized by 
IST-9 and  FN-3  are localized within the NH2 part of the 
fragment lost in the thermolysin digestion: the ED sequence. 
Using these monoclonals (IST-9 and FN-3) in a quantita- 
tive assay, we demonstrated, at the protein level, that this se- 
quence is not present in plFN, and that FN from tumor-de- 
rived and SV-40-transformed human cells is composed of a 
population of molecules in which the percentage of subunits 
containing the ED sequence is about 10 times higher than in 
FN  from  normal  human  fibroblasts.  Similarly,  FN  from 
transformed cells is composed of a population of molecules 
in which the IIlCS sequence is more expressed than in FN 
from normal cells (3). This may be due to either a  slower 
catabolism or an increased synthesis of FN molecules con- 
taining the ED or IHCS sequences. The fact that FN mole- 
cules containing these two sequences are much more suscep- 
tible to proteolytic enzymes rules out the first hypothesis. 
Thus, these results strongly suggest that in transformed cells 
the mechanisms that regulate RNA processing are altered. 
Of course, this needs to be confirmed at the mRNA level. 
Table II. Competitive Inhibition Binding of  Monoclonals 
IST-9 and IST-4 to Human cFN 
FN required to give 
50% inhibition 
FN source  IST-9  IST-4 
#g 
Plasma  >100  0.29 
Normal human fibroblasts 
(LZ)  9.7  0.31 
Normal human fibroblasts 
(GM 5386)  11.2  0.28 
Normal human fibroblasts 
(GM 3651)  10.3  0.37 
Normal human fibroblasts 
(WI38)  8.4  0.25 
SV40-transformed fibroblasts 
(WI38WA13)  0.9  0.25 
Rhabdomyosarcoma 
(RD)  0.85  0.32 
Melanoma 
(IgR3)  1.2  0.33 
Fibrosarcoma 
(HT-1080)  1.0  0.30 
The experiments were carried out using the double-antibody  radioimmunoas- 
say described in Materials and Methods. 
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Figure 3. Schematic represen- 
tation  of thermolysin  diges- 
tion  of  FN  subunits.  Ther- 
molysin  digestion  on  IST-9- 
Sepharose of the FN subunits 
(A) containing and (B) lacking 
the II/CS sequence, and of the 
subsequent thermolysin diges- 
tion  in  solution  of the  frag- 
ments obtained.  Amino acids 
of the  NH2- and COOH-ter- 
minal  of different  fragments 
are also indicated. COOH-ter- 
mini  are  from references  20 
and 21. The model is based on 
data reported here and in ref- 
erences 3, 20, and 21. Also in- 
dicated are the types of inter- 
nal homology (22). 
The results reported here raise three questions: (a) Do tu- 
mor cells also express higher levels of the ED sequence in 
vivo? (b) Are the different fibronectin variants produced by 
malignant cells at least partially responsible for the expres- 
sion of the transformed phenotype? (c) Are modifications of 
pre-mRNA splicing in malignant cells limited to FN or is it 
a more general phenomenon involving other proteins? 
Such mAbs specific to sequences, the expression of which 
is regulated by the alternative splicing of pre-mRNA, may 
represent tools useful for answering these questions. 
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